Knowledge management for efficient quantitative analyses during regulatory reviews

Knowledge management comprises the strategies and methods employed to generate and leverage knowledge within an organization. This report outlines the activities within the Division of Pharmacometrics at the US FDA to effectively manage knowledge with the ultimate goal of improving drug development and advancing public health. The infrastructure required for pharmacometric knowledge management includes provisions for data standards, queryable databases, libraries of modeling tools, archiving of analysis results and reporting templates for effective communication. Two examples of knowledge management systems developed within the Division of Pharmacometrics are used to illustrate these principles. The benefits of sound knowledge management include increased productivity, allowing reviewers to focus on research questions spanning new drug applications, such as improved trial design and biomarker development. The future of knowledge management depends on the collaboration between the FDA and industry to implement data and model standards to enhance sharing and dissemination of knowledge.

[1]  Norman Stockbridge,et al.  Concentration‐QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review , 2008, Journal of clinical pharmacology.

[2]  B P Booth,et al.  Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development , 2009, Clinical pharmacology and therapeutics.

[3]  Christine E Garnett,et al.  Population Pharmacokinetic and Concentration—QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies , 2011, Journal of clinical pharmacology.

[4]  Yaning Wang,et al.  Leveraging Prior Quantitative Knowledge to Guide Drug Development Decisions and Regulatory Science Recommendations: Impact of FDA Pharmacometrics During 2004–2006 , 2008, Journal of clinical pharmacology.

[5]  Ohidul Siddiqui,et al.  Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease , 2009, The AAPS Journal.

[6]  C. Garnett,et al.  Considerations for Clinical Trial Design and Data Analyses of Thorough QT Studies Using Drug‐Drug Interaction , 2010, Journal of clinical pharmacology.

[7]  Lawrence J Lesko,et al.  Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.

[8]  Yaning Wang,et al.  Creation of a Knowledge Management System for QT Analyses , 2011, Journal of clinical pharmacology.

[9]  L. Naeger,et al.  Antiviral Information Management System (AIMS): A Prototype for Operational Innovation in Drug Development , 2010, Journal of clinical pharmacology.

[10]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.